Takeda Pharmaceutical Company Limited הודיעה היום שהתקשרה בהסכם למכירת תיק נכסים נבחרים של תרופות OTC
(ללא מרשם) ועם מרשם במספר מדינות במזרח הקרוב, המזרח התיכון ואפריקה (NEMEA)
שביחידה העסקית שוקי צמיחה ומתעוררים שלה ל- Acino תמורת
שווי כולל שעולה על 200 מיליון דולר אמריקני. זאת העסקה השלישית בשנת הכספים 2019
שמקדמת את האסטרטגיה של טקדו להתמקד בתחומים עסקיים שליבתיים לצמיחה שלה בטווח
הארוך ולאפשר הפחתת מינוף מהירה אחרי שרכשה את שייר.
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD
Transaction
accelerates deleveraging
Agreement
simplifies portfolio in Takeda’s NEMEA region
OSAKA, Japan, 15 October 2019, (BUSINESS WIRE):
Takeda
Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced
that it has entered into an agreement to divest a portfolio of select
over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near
East, Middle East and Africa (NEMEA) countries within its Growth and Emerging
Markets Business Unit to Acino for a total value in
excess of $200 million USD. This is the third transaction in FY19 that furthers
Takeda’s strategy to focus on business areas core to its long-term growth and
facilitate rapid deleveraging following its acquisition of Shire.
“The
divestment of non-core assets sold in NEMEA represents the continued execution
of our strategy to optimize our portfolio, invest in the defined core business
areas, and accelerate our progress toward reaching our target leverage ratio,”
said Costa Saroukos, Chief Financial Officer, Takeda.
While
these products continue to play important roles in meeting patient needs, they
are primarily outside of Takeda's chosen business areas – Gastroenterology
(GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience – core
to its global long-term growth.
“Takeda
remains committed to this region, as we continue our work in accelerating access
to our life-changing portfolio of innovative products to meet the needs of
patients. We will do this via our commercial activities and Takeda’s Access to
Medicines program,” said Ricardo Marek, President, Growth and Emerging Markets
Business Unit, Takeda. "We are confident that Acino is best positioned to
provide uninterrupted access and supply of the divested products to patients.”
Takeda
intends to use the proceeds from this divestiture to reduce debt and continue
to deleverage towards its target of 2.0x net debt/adjusted EBITDA over the next
three to five years. Takeda is committed to rapid deleveraging driven by strong
cash flow and divestiture proceeds, while also simplifying its portfolio.
Transaction
Details
Takeda
has agreed to sell a portfolio of approximately 30 select prescription
pharmaceutical and OTC products sold in the NEMEA region to Acino, a Swiss
pharmaceutical company headquartered in Zurich, with a clear focus on selected
markets in the Middle East, Africa, the CIS Region, and Latin America. The
following key countries are included in the agreement: Egypt, Saudi Arabia,
South Africa, Turkey, Ukraine and United Arab Emirates, as well as other
countries.
Under
the terms of the agreement, Acino will acquire the rights, title, and interest
to the products in the portfolio exclusive to these countries. It is
anticipated that primarily sales and marketing professionals supporting the
portfolio will transition to Acino at closing of the transaction. The parties
will also enter into a multi-year manufacturing and supply agreement, under
which Takeda will continue to manufacture the products on behalf of Acino.
The
transaction is expected to close in Q4 FY19 (January - March 2020), subject to
the satisfaction of customary closing conditions including receipt of
applicable antitrust approvals. Until then, these products will continue to be
made available by Takeda.
Takeda
is being advised by BofA Securities (financial advisor), White & Case
(legal advisor), and Deloitte (financial consultant) in this transaction.
About
Takeda Pharmaceutical Company Limited
Takeda
Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) is a global, values-based,
R&D-driven biopharmaceutical leader headquartered in Japan, committed to
bringing Better Health and a Brighter Future to patients by translating science
into highly-innovative medicines. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare
Diseases. We also make targeted R&D investments in Plasma-Derived Therapies
and Vaccines. We are focusing on developing highly innovative medicines that
contribute to making a difference in people's lives by advancing the frontier
of new treatment options and leveraging our enhanced collaborative R&D
engine and capabilities to create a robust, modality-diverse pipeline. Our
employees are committed to improving quality of life for patients and to
working with our partners in health care in approximately 80 countries and
regions.
For
more information, visit https://www.takeda.com
Forward-Looking
Statements
This
press release and any materials distributed in connection with this press
release may contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of operations, including
estimates, forecasts, targets and plans for Takeda. Without limitation,
forward-looking statements often include words such as “targets”, “plans”,
“believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”,
“will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”,
“projects” or similar expressions or the negative thereof. Forward-looking
statements in this document are based on Takeda’s estimates and assumptions
only as of the date hereof. Such forward-looking statements do not represent
any guarantee by Takeda or its management of future performance and involve
known and unknown risks, uncertainties and other factors, including but not
limited to: the economic circumstances surrounding Takeda’s global business,
including general economic conditions in Japan and the United States;
competitive pressures and developments; changes to applicable laws and
regulations; the success of or failure of product development programs;
decisions of regulatory authorities and the timing thereof; fluctuations in
interest and currency exchange rates; claims or concerns regarding the safety
or efficacy of marketed products or product candidates; the timing and impact
of post-merger integration efforts with acquired companies; and the ability to
divest assets that are not core to Takeda’s operations and the timing of any
such divestment(s), any of which may cause Takeda’s actual results,
performance, achievements or financial position to be materially different from
any future results, performance, achievements or financial position expressed
or implied by such forward-looking statements. For more information on these
and other factors which may affect Takeda’s results, performance, achievements,
or financial position, see “Item 3. Key Information—D. Risk Factors” in
Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports
filed with the U.S. Securities and Exchange Commission, available on Takeda’s
website at: https://www.takeda.com/investors/reports/sec-filings/
or at www.sec.gov.
Future results, performance, achievements or financial position of Takeda could
differ materially from those expressed in or implied by the forward-looking
statements. Persons receiving this press release should not rely unduly on any
forward-looking statements. Takeda undertakes no obligation to update any of
the forward-looking statements contained in this press release or any other
forward-looking statements it may make, except as required by law or stock
exchange rule. Past performance is not an indicator of future results and the
results of Takeda in this press release may not be indicative of, and are not
an estimate, forecast or projection of Takeda’s future results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191014005742/en/
אין תגובות:
הוסף רשומת תגובה
שים לב: רק חברים בבלוג הזה יכולים לפרסם תגובה.